CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 119 enrolled
Drug / intervention
Digital cognitive behavioral therapydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05330312
NCT05330312N/ACompleted

A Randomized, Controlled, Parallel-group Clinical Investigation Evaluating the Impact of Digital Cognitive Behavioural Therapy on Psychological Symptom Burden in Adults Diagnosed With Pulmonary Fibrosis

Vicore Pharma AB·interventional·Posted Apr 15, 2022·Updated Sep 24, 2024

In Brief

A clinical study evaluating Digital cognitive behavioral therapy for Pulmonary Fibrosis and Anxiety. Completed, enrolled 119 participants across 2 sites.

Detailed Summary

The purpose of the study is to assess efficacy and safety of a digital cognitive behavioural therapy for patients with pulmonary fibrosis on anxiety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCurebase Inc.

Timeline

N/ACompletedFinished
2023202420252026
First PostedApr 15, 2022
Enrollment StartApr 17, 2022
Primary CompletionOct 19, 2023
Study CompletionNov 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4.2 years ago

Interventions

Digital cognitive behavioral therapydevice

Therapy for patients with pulmonary fibrosis